Research programme: cannabinoid prodrugs - Vitality BiopharmaAlternative Names: Cannabinosides - Vitality Biopharma
Latest Information Update: 22 Nov 2016
At a glance
- Originator Vitality Biopharma
- Class Antiepileptic drugs; Cannabinoids
- Mechanism of Action Cannabinoid receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Epilepsy; Guillain-Barre syndrome; Huntington's disease; Inflammatory bowel diseases; Pain; Schizophrenia